Author Archives: Steve Bryson PhD

FDA Approves Actemra to Treat Adults With SSc-ILD

The U.S. Food and Drug Administration (FDA) has approved Actemra (tocilizumab) to slow lung function decline in adults with systemic sclerosis-associated interstitial lung disease (SSc-ILD). “We are honored to offer the very first FDA-approved biologic treatment option to…

Early Use of Triple Combo Seen to Treat Diffuse Cutaneous Scleroderma

A triple combination of prednisolone, cyclophosphamide and plasma exchange (plasmapheresis) was effective against skin thickening in seven of eight people with diffuse cutaneous systemic sclerosis (dcSSc), a case series study reports. These results support further investigation into treating newly diagnosed dcSSc patients with this combination…